Company Encyclopedia
View More
name
JINGFENG PHARMACEUTI
000908.SZ
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company’s principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic equipment and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the fields of cardiovascular disease, orthopedic pain disease, tumor disease, women and children.
3.120 T
000908.SZMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking192/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-264.36%E
    • Profit Margin39.82%A
    • Gross Margin62.97%A
  • Growth ScoreC
    • Revenue YoY-1.15%D
    • Net Profit YoY162.76%A
    • Total Assets YoY-14.27%E
    • Net Assets YoY85.50%A
  • Cash ScoreC
    • Cash Flow Margin251.14%C
    • OCF YoY-1.15%D
  • Operating ScoreC
    • Turnover0.41C
  • Debt ScoreE
    • Gearing Ratio104.30%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ST JINGFENG hit the daily limit down during trading, performing a "Heaven and Earth Board," currently reported at 7.67 yuan, with a transaction amount of 415 million yuan

    Zhitong·
    SZ
    000908
    -0.38%
    Zhitong·
    SZ
    000908
    -0.38%

    JINGFENG PHARMACEUTI: The controlling shareholder's partial shares have been unfrozen and the pending freeze has taken effect

    JINGFENG PHARMACEUTI announced that the judicial freeze and pending freeze on some shares of its controlling shareholder Ye Xiangwu have been lifted. On October 22, 2025, 19.7175 million shares were unfrozen, accounting for 17.57% of his holdings; 4.1066 million shares are subject to a pending freeze, accounting for 3.66% of his holdings. As of the announcement date, Ye Xiangwu and his concerted parties have a total of 24.3506 million shares frozen, accounting for 21.23% of his holdings. This change will not lead to a change in the company's control, but there is a risk of disposal, and control may be unstable

    Zhitong·
    SZ
    000908
    -0.38%
    Zhitong·
    SZ
    000908
    -0.38%

    ST JINGFENG hit the daily limit during trading, performing a "ceiling" move, currently reported at 7.05 yuan, with a transaction volume of 425 million yuan

    Zhitong·
    SZ
    000908
    -0.38%
    Zhitong·
    SZ
    000908
    -0.38%

    ST JINGFENG stock trading will be subject to delisting risk warning on October 23

    ST JINGFENG announced that due to the Changde Intermediate Court's ruling to accept the creditors' application for the company's reorganization, its stock will be subject to delisting risk warning on October 23, 2025, and the stock abbreviation will be changed to "*ST JINGFENG". The stock will be suspended for one day on October 22, 2025, and will resume trading on October 23, with a daily price fluctuation limit of 5%

    Zhitong·
    SZ
    000908
    -0.38%
    Zhitong·
    SZ
    000908
    -0.38%

    JINGFENG PHARMACEUTI: Selling subsidiary equity, transfer price is 142,500 yuan

    ST JINGFENG announced that the company plans to transfer 51% equity of Jiangxi Yanhua Pharmaceutical Co., Ltd. held by its subsidiary Shanghai JINGFENG Pharmaceutical Co., Ltd. to Jiangxi Shaoyang Pharmaceutical Co., Ltd. for a price of RMB 142,500. After the completion of this transaction, Jiangxi Yanhua will no longer be included in the company's consolidated financial statements. The operating income of the transaction target for the year 2024 is RMB 43.5759 million, accounting for 10.47% of the company's audited operating income for the most recent fiscal year

    Zhitong·
    SZ
    000908
    -0.38%
    Zhitong·
    SZ
    000908
    -0.38%
    © 2025 Longbridge｜Disclaimer